Mar. 20 at 12:00 PM
$ZOMDF $SPY $BTCN.X
$SOXL $JEPQ
Zomedica is quietly building a bridge the market still doesn’t get.
They already did:
•
$32M revenue
•
$10.5M record Q4
• 68% margins
•
$53M cash
•
$3.1M Development Services across animal + human health
Then they land Boehringer Animal Health USA — while Boehringer itself is a healthcare giant doing €20.8B in Human Pharma and €4.7B in Animal Health.
And the CEO? 35+ years in human medtech/biotech.
That does not mean a human-health jackpot is already announced.
It means the pieces are now on the table:
real revenue, real validation, real services, real cash, real experience.
That’s not a random OTC.
That’s a platform story the market still hasn’t priced correctly.